SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-044400
Filing Date
2023-12-11
Accepted
2023-12-11 16:30:44
Documents
19
Period of Report
2023-12-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49396
2 ex4-1.htm EX-4.1 116072
3 ex4-2.htm EX-4.2 121393
4 ex4-3.htm EX-4.3 121398
5 ex10-1.htm EX-10.1 258835
6 ex10-2.htm EX-10.2 62395
7 ex99-1.htm EX-99.1 18910
8 ex99-1_001.jpg GRAPHIC 3944
  Complete submission text file 0001493152-23-044400.txt   1077896

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE zvsa-20231206.xsd EX-101.SCH 3012
10 XBRL LABEL FILE zvsa-20231206_lab.xml EX-101.LAB 34240
11 XBRL PRESENTATION FILE zvsa-20231206_pre.xml EX-101.PRE 22357
13 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3431
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 231478554
SIC: 2834 Pharmaceutical Preparations